These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 27585940)

  • 1. A single untimed plasma drug concentration measurement during low-level HIV viremia predicts virologic failure.
    Gonzalez-Serna A; Swenson LC; Watson B; Zhang W; Nohpal A; Auyeung K; Montaner JS; Harrigan PR
    Clin Microbiol Infect; 2016 Dec; 22(12):1004.e9-1004.e16. PubMed ID: 27585940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation.
    Laprise C; de Pokomandy A; Baril JG; Dufresne S; Trottier H
    Clin Infect Dis; 2013 Nov; 57(10):1489-96. PubMed ID: 23946221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure.
    Swenson LC; Min JE; Woods CK; Cai E; Li JZ; Montaner JS; Harrigan PR; Gonzalez-Serna A
    AIDS; 2014 May; 28(8):1125-34. PubMed ID: 24451160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-level viremia and virologic failure in persons with HIV infection treated with antiretroviral therapy.
    Fleming J; Mathews WC; Rutstein RM; Aberg J; Somboonwit C; Cheever LW; Berry SA; Gebo KA; Moore RD;
    AIDS; 2019 Nov; 33(13):2005-2012. PubMed ID: 31306175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and predictive value of intermittent viremia with combination hiv therapy.
    Havlir DV; Bassett R; Levitan D; Gilbert P; Tebas P; Collier AC; Hirsch MS; Ignacio C; Condra J; Günthard HF; Richman DD; Wong JK
    JAMA; 2001 Jul; 286(2):171-9. PubMed ID: 11448280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of HIV-1 drug resistance testing at low-level viremia and its ability to predict future virologic outcomes and viral evolution in treatment-naive individuals.
    Gonzalez-Serna A; Min JE; Woods C; Chan D; Lima VD; Montaner JS; Harrigan PR; Swenson LC
    Clin Infect Dis; 2014 Apr; 58(8):1165-73. PubMed ID: 24429436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with high-risk low-level viremia leading to virologic failure: 16-year retrospective study of a Chinese antiretroviral therapy cohort.
    Zhang T; Ding H; An M; Wang X; Tian W; Zhao B; Han X
    BMC Infect Dis; 2020 Feb; 20(1):147. PubMed ID: 32066392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART.
    Nettles RE; Kieffer TL; Kwon P; Monie D; Han Y; Parsons T; Cofrancesco J; Gallant JE; Quinn TC; Jackson B; Flexner C; Carson K; Ray S; Persaud D; Siliciano RF
    JAMA; 2005 Feb; 293(7):817-29. PubMed ID: 15713771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ultrasensitive assessment of residual low-level HIV viremia in HAART-treated patients and risk of virological failure.
    Maggiolo F; Callegaro A; Cologni G; Bernardini C; Velenti D; Gregis G; Quinzan G; Soavi L; Iannotti N; Malfatto E; Leone S
    J Acquir Immune Defic Syndr; 2012 Aug; 60(5):473-82. PubMed ID: 22481602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.
    Swindells S; DiRienzo AG; Wilkin T; Fletcher CV; Margolis DM; Thal GD; Godfrey C; Bastow B; Ray MG; Wang H; Coombs RW; McKinnon J; Mellors JW;
    JAMA; 2006 Aug; 296(7):806-14. PubMed ID: 16905786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of virological failure in HIV-1-infected patients experiencing low-level viraemia under active antiretroviral therapy (ANRS C03 cohort study).
    Vandenhende MA; Perrier A; Bonnet F; Lazaro E; Cazanave C; Reigadas S; Chêne G; Morlat P;
    Antivir Ther; 2015; 20(6):655-60. PubMed ID: 25735799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 second-line failure and drug resistance at high-level and low-level viremia in Western Kenya.
    Kantor R; DeLong A; Schreier L; Reitsma M; Kemboi E; Orido M; Obonge S; Boinett R; Rono M; Emonyi W; Brooks K; Coetzer M; Buziba N; Hogan J; Diero L
    AIDS; 2018 Nov; 32(17):2485-2496. PubMed ID: 30134290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and significance of HIV-1 drug resistance mutations among patients on antiretroviral therapy with detectable low-level viremia.
    Li JZ; Gallien S; Do TD; Martin JN; Deeks S; Kuritzkes DR; Hatano H
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5998-6000. PubMed ID: 22890763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-Level Viremia among Adults Living with HIV on Dolutegravir-Based First-Line Antiretroviral Therapy Is a Predictor of Virological Failure in Botswana.
    Bareng OT; Moyo S; Mudanga M; Sebina K; Koofhethile CK; Choga WT; Moraka NO; Maruapula D; Gobe I; Motswaledi MS; Musonda R; Nkomo B; Ramaabya D; Chebani T; Makuruetsa P; Makhema J; Shapiro R; Lockman S; Gaseitsiwe S
    Viruses; 2024 May; 16(5):. PubMed ID: 38793602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rate of virologic failure and selection of drug resistance mutations using different triple nucleos(t)ide analogue combinations in HIV-infected patients.
    Martín-Carbonero L; Gil P; García-Benayas T; Barreiro P; Blanco F; de Mendoza C; Maida I; González-Lahoz J; Soriano V
    AIDS Res Hum Retroviruses; 2006 Dec; 22(12):1231-5. PubMed ID: 17209764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistent Low-level Viremia While on Antiretroviral Therapy Is an Independent Risk Factor for Virologic Failure.
    Joya C; Won SH; Schofield C; Lalani T; Maves RC; Kronmann K; Deiss R; Okulicz J; Agan BK; Ganesan A
    Clin Infect Dis; 2019 Nov; 69(12):2145-2152. PubMed ID: 30785191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low Incidence of HIV-1C Acquired Drug Resistance 10 Years after Roll-Out of Antiretroviral Therapy in Ethiopia: A Prospective Cohort Study.
    Mulu A; Maier M; Liebert UG
    PLoS One; 2015; 10(10):e0141318. PubMed ID: 26512902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors.
    Knobel H; Guelar A; Carmona A; Espona M; González A; López-Colomés JL; Saballs P; Gimeno JL; Díez A
    AIDS Patient Care STDS; 2001 Apr; 15(4):193-9. PubMed ID: 11359661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
    Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
    J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.